o Result of the votes at Theradiag's Annual and Extraordinary General Meeting

o Change in the composition of the Board of Directors chaired by Gérard Tobelem

o The Board of Directors reaffirms its confidence in the CEO
o Update regarding the HOB Biotech situation

Croissy-Beaubourg, June 5, 2018, 8am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announces the results of the voting at its Ordinary Annual and Extraordinary General Meeting.

Results of the voting at the Ordinary Annual and Extraordinary General Meeting

The Company' Ordinary Annual and Extraordinary General Meeting was held on May 29, 2018 in the offices of the Fieldfisher law firm, 48 rue Cambon, 75001 Paris, France. The number of shares held by shareholders present or represented at the Meeting was 2,536,253, giving a quorum of 29.27%.

The results of the votes of Theradiag's shareholders at this Meeting were as follows:

	Resolution $n^{\circ}$	Resolution	N° of votes FOR	$N^{\circ}$ of abstentions AGAINST	N° of votes	Votes	%	Result of the vote
Ordinary General Meeting	$\mathbf 1$ $\overline{2}$	Approval of financial statements	1,585,315	$\mathbf{0}$	1,057,066	or	60.00%	Adopted
						Against	40.00%
		Approval of consolidated accounts	1,901,125	$\Omega$	741,256	-or	71.95%	Adopted
						Against	28.05%
	3	Approval of expenses and liabilities (art. 39 CGI)	2,642,381	$\mathbf 0$ 0	$\mathbf 0$	For	100.00%	Adopted Adopted
						Against	0.00% 71.93%
	4	Allocation of 2017 annual income	1,900,612		741,769	For Against	28.07%
				$\mathbf 0$	713	For	99.97%
	5	Approval of regulated agreements	2,641,668			Against	0.03%	Adopted
						For	45.38%
	6 $\overline{7}$	Renewal of Mr. Michel FINANCE as a Director Renewal of Mr. Pierre MORGON as a Director	1,199,100 1,885,253	578,375 $\mathbf 0$	864,906 757,128	Abstentions	21.89%	Rejected Adopted
						Against	32.73%
						For	71.35%
						Against	28.65%
	8 9 10 11	Renewal of Mr. Vincent FERT as a Director Removal of Mr. John LI Renewal of the Company's statutory auditors Renewal of the Company's alternate statutory auditors	1,892,563 1,318,087 1,897,763 2,641,468	$\mathbf 0$ $\mathbf 0$ $\mathbf 0$ $\mathbf 0$	749,818 1,324,294 744,618 913	-or	71.62%	Adopted Rejected Adopted Adopted
						Against	28.38%
						For	49.88% 50.12%
						Against -or	71.82%
						Against	28.18%
						For	99.97%
						Against	0.03%
	12 13	Setting of Board members' attendance fees Share buyback	2,514,681 1,860,953	$\mathbf 0$ $\mathbf 0$	127,700 781,428	For	95.17%	Adopted Adopted
						Against	4.83%
						For	70.43%
						Against	29.57%
Extraordinary General Meeting	14	Decision not to dissolve early	2,642,381	$\mathbf 0$	$\mathbf 0$	-or	100.00%	Adopted
						Against For	0.00% 65.62%
	15	Capital increase with pre-emptive subscription rights	1,733,840	713	907,828	Abstentions	0.03%	Rejected
						Against	34.36%
	16	Capital increase without pre-emptive subscription rights via a public offering	789,609	0	1,852,772	For	29.88%	Rejected
						Against	70.12%
	17	Capital increase without pre-emptive	791,072	$\mathbf 0$	1,851,309	For	29.94%	Rejected
		subscription rights via a private placement				Against	70.06%
	18	Capital increase without pre-emptive		0	1,924,584	For	27.16%	Rejected
		subscription rights for certain categories of beneficiaries	717,797			Against	72.84%
	19	Increase in the number of shares by virtue of the 4 previous resolutions	1,617,055	$\mathbf 0$	1,025,326	For	61.20%	Rejected
						Against	38.80%
	20 21 22	Free share allotment Capital increase reserved for employees Setting of the global ceiling	1,529,438 635,267 1,737,103	0 0 $\mathbf 0$	1,112,943 2,007,114 905,278	For	57.88%	Rejected
						Against	42.12%
						For Against	24.04% 75.96%	Rejected
						-or	65.74%
						Against	34.26%	Rejected
	23	Reduction in the share capital via the ancellation of shares	1,576,466	315,810	750,105	For	59.66%	Rejected
						Abstentions	11.95%
						Against	28.39%
	24	Powers to carry out formalities	2,325,858	316,523	$\mathbf 0$	For	88.02%	Adopted
						Abstentions	11.98%
						Against	0.00%
Ordinary General Meeting (resolutions tabled on HOB Biotech Group Corp. Ltd's request)	25	Removal of Mr. Michel FINANCE (Resolution that became void during the AGM)	$\mathbf 0$	$\mathbf 0$	$\mathbf 0$	For Against	÷, ÷,
	26	Removal of Mr. Gérard TOBELEM	867,866	578,375	1,196,140 Abstentions	For	32.84%	Rejected
							21.89%
						Against	45.27%
	27	Appointment of Mrs. Sylvie BRATEL as a Director	1,449,568 $\mathsf{O}\xspace$	4,000 $\mathsf{O}\xspace$	$\mathsf 0$	For	54.86%	Adopted
						1,188,813 Abstentions	0.15%
						Against	44.99%
	28	Appointment of HOB BIOTECH as a Director				For
		(Resolution that became void during the AGM)				Against	$\overline{\phantom{a}}$

Change in the composition of the Board of Directors

Following this AGM, Theradiag's Board of Directors still comprises seven members and has just one new member, Sylvie Bratel, who has declared herself to be an independent director. The composition of the Board of Directors is thus now as follows:

Gérard Tobelem, Chairman of the Board
Sylvie Bratel, Independent Director
Dominique Costantini, Independent Director
Vincent Fert, Independent Director
John Li, Director
Pierre Morgon, Independent Director
Dominique Takizawa, Independent Director

After completing engineering degrees in France and the United States, in 1982 Sylvie Bratel joined Banque Nationale de Paris to work on technological innovation projects. She continued her career with the General Inspectorate and the Balance Sheet Management department before joining the Caisse des Dépôts et Consignation group in 1995, where she worked in the Competitive Banking Activities and Strategy departments. She participated in the creation of CDC-Markets before steering merger operations with Groupe Caisse d'Epargne and Groupe des Banques Populaires with the creation of Natixis. From 2009 to 2014, Sylvie Bratel was Head of Strategy for British insurance company Aviva's French subsidiary and then VP of its life insurance subsidiary Aviva Vie. Since 2014, Sylvie Bratel, independent director, has been IFA and EcoDa certified.

The Board of Directors reaffirms its confidence in the CEO

At its meeting of June 4, 2018, the Board of Directors confirmed Michel Finance's mandate as CEO and reaffirmed its full and complete confidence in him.

Update regarding the HOB Biotech situation

HOB Biotech's failure to comply with the terms of the 2015 contractual agreements signed by both companies has led to Theradiag being unable to distribute the agreed products in Europe or to market its reagents in China. Because of the loss suffered by Theradiag, legal proceedings have been initiated against HOB Biotech in order to obtain compensation.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Theradiag Investor Relations Fabienne François CFO Tel.: +33 (0)1 64 62 10 12 [email protected]

NewCap Financial Communications & Investor Relations Valentine Brouchot Tel.: +33 (0)1 44 71 94 94 [email protected]

Alize RP Press Relations Caroline Carmagnol Tel.: +33 (0)1 44 54 36 64 [email protected]

AI Terminal

Theradiag

1702_iss_2018-06-05_0a777aad-a5db-4f7e-b67c-6bade835b79b.pdf